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Aims/hypothesis—Monoclonal antibodies to proprotein convertase subtilisin/kexin type 9 
(PCSK9) significantly lower the levels of LDL and very low-density lipoproteins, but their effect on 
postprandial lipoprotein metabolism in dyslipidemic subjects is unclear. We investigated the effects 
of evolocumab on postprandial lipid responses, ectopic fat depots, whole body cholesterol synthesis, 
hepatic lipogenesis, and fat oxidation in patients with type 2 diabetes.  
Methods—The trial was a single-phase, nonrandomized study of 12-week treatment with 
evolocumab 140 mg s.c. Q2W in 15 patients with type 2 diabetes on background statin therapy. 
Cardiometabolic responses to a high-fat mixed meal were assessed before and at the end of the 
intervention period. 
Results— Evolocumab treatment reduced significantly postprandial rises in plasma total 
triglyceride (by 21%, P<0.0001) and VLDL1-triglyceride (by 15%, P=0.018), but the increase in 
chylomicron-triglyceride following the meal was not significantly perturbed (P=0.053). There were 
reduced postprandial responses in plasma total apoC-III (by 14%, P<0.0001), apoB48 concentration 
(by 17%, P=0.0046) and in ‘remnant-like particles (RLP)’ cholesterol (by 29%, P<0.0001) on the 
PCSK9 inhibitor. Treatment reduced the steady state (i.e. fasting and postprandial) concentrations 
of VLDL2 cholesterol by 50% (P<0.0001) and VLDL2 triglyceride by 29% (P<0.0001), in addition 
to the 78% reduction of LDL cholesterol (P<0.001). The changes in apoC-III associated significantly 
with reduction in postprandial responses of RLP-cholesterol and TRL-cholesterol. Evolocumab 
therapy did not influence liver fat accumulation, hepatic de novo lipogenesis or fasting β-
hydroxybutyrate, but did increase total body cholesterol synthesis (P<0.01). 
Conclusions—Evolocumab treatment improved postprandial responses of TRLs and measures of 
cholesterol-enriched remnant particles in type 2 diabetic subjects. These results indicate that 
postprandial phenomena need to be taken into account in assessing the full range of actions of 
PCSK9 inhibitors in dyslipidemic individuals.  
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Despite major advances in therapy, atherosclerotic cardiovascular disease (ASCVD) and its clinical 
manifestations such as myocardial infarction and ischaemic stroke are still the leading causes of 
mortality and morbidity globally.1 Both epidemiological and genetic studies have established that an 
increased level of cholesterol-rich LDL is the principal risk factor for developing ASCVD.1 
However, in recent years there has been a growing awareness of the atherogenic potential and hence 
clinical importance of postprandial lipoproteins based on the findings of epidemiological studies that 
have identified postprandial hypertriglyceridemia as an independent risk for coronary 
atherosclerosis.2-11 
The hypertriglyceridemia that develops following dietary lipid absorption comprises increased levels 
of intestinally derived apoB48-containing chylomicrons (CM) and their remnants, and liver derived 
apoB100-containing very low density lipoproteins (VLDL) and their remnants.12 Chylomicrons 
transport dietary lipids to adipose, cardiac, and skeletal muscle tissue, where their triglyceride 
components are hydrolysed by lipoprotein lipase (LPL), releasing the fatty acids for uptake by 
tissues.13 When a large portion of the triglycerides has been hydrolysed, cholesterol-enriched 
chylomicron remnants are formed. These remnant particles are cleared by the liver via the LDL 
receptor (LDL-R), the LDL receptor-related protein (LRP) and heparan sulphate proteoglycans 
(HSPG).13 Angiopoietin-like protein 3 (ANGPTL3) and apoC-III have emerged as important 
metabolic regulators of the metabolism of triglyceride-rich lipoproteins (TRLs) and novel candidate 
targets for intervention to correct the dyslipidaemia and ameliorate CVD risk. The impact of apoC-
III on TRL metabolism and atherogenesis has been linked to both LPL-mediated mechanisms and 
indirect mechanisms, such as increased secretion of TRLs, proinflammatory responses in vascular 
cells and impaired LPL-independent hepatic clearance of TRL remnants.14 
As humans spend most of the waking day in the postprandial state, effective lipid lowering therapies 
must take account of the potential impact on all atherogenic lipoproteins, including the components 
of postprandial hypertriglyceridemia. Importantly, the postprandial triglyceride response in type 2 
diabetic subjects is considerably increased and prolonged relative to non-diabetic subjects.15, 16 This 
component of the diabetic dyslipidemia likely contributes to the residual risk in statin-treated type-
2 diabetic subjects. Indeed, genetic studies suggest that not only LDL, but also TG-rich remnants are 
directly causal in ASCVD, independent of LDL-C levels.10, 17  Therefore, there is need for aggressive 
lipid lowering in people with type 2 diabetes and very high-risk.18, 19 Statins by upregulating LDL 
receptors, and potentially other hepatic receptors, increase clearance of both LDL particles and of 
CM and VLDL remnants. These drugs have been shown to lower fasting and postprandial plasma 
triglyceride and apoB48 concentrations.20-22 Monoclonal antibodies to proprotein convertase 
subtilisin/kexin type 9 (PCSK9) significantly lower LDL and fasting TRL levels,23-26 but their effect 
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on postprandial lipid metabolism has not yet been elucidated fully for individuals with 
dyslipidaemia. Plasma PCSK9 concentration associates with postprandial TRL metabolism,27 and 
recent results from the BANTING study in type 2 diabetics gave an indication that inhibition of 
PCSK9 with monoclonal antibodies reduced levels of postprandial lipids and apoproteins including 
VLDL-cholesterol, chylomicron triglyceride and apoB48.28 In contrast, kinetic studies with stable 
isotopes in normolipemic subjects found no impact of PCSK9 inhibition on postprandial plasma 
triglycerides or apoB48 concentrations.29 Likewise, Chan et al recently reported that this therapy, 
again in subjects with normal plasma triglyceride levels, had no significant effect on the response to 
a fat meal challenge in postprandial plasma triglycerides and apoB48.22  
The end-products of cholesterol utilization are the bile acids.30 In fact, the synthesis of bile acids is 
the major route of cholesterol catabolism in mammals. Although several of the enzymes involved in 
bile acid synthesis are active in many cell types, the liver is the only organ where their complete 
biosynthesis can occur.30 Interestingly, despite the marked effect on cholesterol homoeostasis, statins 
do not alter plasma bile acid levels. PCSK9 inhibition markedly augments the LDL lowering action 
of statins, and it has been hypothesized that combined PCSK9 and HMG-CoA reductase inhibition 
may alter bile acid metabolism.31 However, studies in mice indicate that hepatocyte cholesterol and 
bile acid homeostasis is maintained with combined anti-PCSK9 and statin intervention through 
efficient liver enzymatic conversion of LDL-derived cholesterol into bile acids and excretion of both, 
with undisturbed enterohepatic recycling.31 Studies in humans are still lacking.  
In the present study, we examined in detail in type 2 diabetics the postprandial effects of PCSK9 
inhibition using evolocumab. In addition, we investigated the action of the drug on cholesterol and 




Study Design―This study was designed as a nonrandomized clinical trial in which subjects were 
examined before and after 12 weeks’ treatment with evolocumab. The study participants were 15 type 
2 diabetics recruited between October 2016 and June 2017 from previous studies and by using an 
online recruitment service provided by Clariness GmbH, Germany. After an initial telephone 
interview of 195 subjects, 77 were invited for a screening visit. Of these, 63 subjects were excluded 
because of failure to meet inclusion criteria. All study subjects used daily stable doses of metformin 
and statin throughout the study period. The protocol comprised two periods: a run-in period and a 
treatment period. The run-in period started at the screening visit when the eligibility to enter the 
treatment period was evaluated. If the subjects were not using statin, or used another statin, 
atorvastatin was initiated at dose of 20 mg/day and this statin run-in period was 4 weeks after the 
change in statin or statin dose. The treatment regimen was continued throughout the study. 
Evolocumab at a dose of 140 mg subcutaneously every 2 weeks (Q2W) was added to the statin 
therapy at the last day of the run-in period and continued over a 12-week treatment period.  
Each study subject underwent a fat-rich mixed meal tolerance test and abdominal magnetic 
resonance imaging before and after the 12-week treatment with evolocumab. Weight and height 
were measured in the study centre after an overnight fast (with subjects barefoot, wearing 
underwear). Waist circumference was recorded at the midpoint between the lower rib margin and 
the iliac crest. Three consecutive readings were taken, and the mean was recorded. Subjects were 
instructed to avoid alcohol and strenuous exercise for 72 hours before each study visit. The 
volunteers also visited the study centre at weeks 2, 4, and 8 for safety blood samples. One study 
subject was excluded during the evolocumab treatment period because of worsening of asthma 
symptoms resulting in oral prednisolone use. Thus, 14 out of the 15 study subjects finished the 
planned protocol. 
The study protocol was approved by ethics committee of Helsinki University Hospital and the 
National Agency of Medicines. Helsinki, Finland (Eruct 2016-00176-30). The trial was undertaken 
in accordance with the Declaration of Helsinki and the European Medicines Agency Note for 
Guidance on good clinical practice. Study subjects signed informed consent before study procedures 
were initiated. 
Inclusion Criteria―Male or female (non-fertile or using medically approved birth control method) 
overweight/obese subjects with type 2 diabetes (T2D) treated with lifestyle counselling and a stable 
dose of metformin (any dose) and atorvastatin (20 mg /day) were eligible for the study. Additional 
inclusion criteria were HbA1c value <=9.0%, BMI between 25−40 kg/m2, age 18−77 yrs. and plasma 
triglycerides between 1.0−4.5 mmol/l and LDL cholesterol >1.8, but < 4.0 mmol/L (on atorvastatin 
20 mg/day).  
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Exclusion Criteria―Exclusion criteria included type 1 diabetes, apoE2/2 phenotype, elevated liver 
enzymes (ALT/AST > 3×UNL), eGFR<60ml/min, clinically significant TSH outside the normal 
range, BMI > 40 kg/m2, HbA1c > 9.0 %, fasting triglyceride >4.5 mmol/l, total cholesterol > 7.0 
mmol/L, positive urine or serum pregnancy test, any other diabetes medication except diet or 
metformin, untreated or inadequately treated hypertension (>160 mmHg systolic and/or >105 mmHg 
diastolic), use of thiazide diuretics at a dose of ≥25 mg/day, lipid-lowering drugs other than statins 
within 3 months, use of estrogen therapy and history/diagnosis of diabetes nephropathy/retinopathy. 
Additional exclusion criteria were history of MI, ACS or coronary revascularization (PCI or CABG) 
within the last 6 months, planned revascularization (e.g., CABG, PCI, carotid or peripheral 
revascularization procedures) within 3 months of screening, NYHA class III/IV congestive heart 
failure persisting despite treatment, history of haemorrhagic stroke, hypersensitivity to evolocumab 
or any of the excipients used in the drug formulation, current use of antithrombotic or anticoagulant 
therapy, known bleeding tendency, and history of cancer within the past 5 years.  
Fat-rich Mixed Meal―Participants were served a fat-rich mixed meal in the morning after an 
overnight fast. The meal consisted of bread, butter, cheese, ham boiled eggs, fresh red pepper, low 
fat milk (1 %), orange juice and tea or coffee and served with a fat-rich cocoa emulsion containing 
40 g olive oil (Amway, Firenze).  The total energy content of the meal averaged 1032 Kcal with 
59.8 % from fat (68.5 grams), 24.4 % from carbohydrate (63.0 grams) and 15.5 % from protein (40.1 
grams). Blood samples were obtained at fasting and at 0.5, 1, 2, 3, 4, 6 and 8 hours after the meal. 
During the test only water was allowed ad libitum and the participants remained physically inactive. 
On the evening before the study day, subjects received 2 g/kg deuterated water (2H2O; Larodan Fine 
Chemicals, Sweden), which was consumed between 18:00 and 22:00 to assess the contribution of 
hepatic de novo lipogenesis (DNL) to fatty acids in VLDL. A blood sample was drawn as a 
background sample in the week before the meal test day. De novo lipogenesis was analysed at 0 h 
and was calculated from enrichment of deuterated water.32, 33  
Proton magnetic resonance Spectroscopy―Proton magnetic resonance spectroscopy was 
performed using a 1.5-T whole-body device to determine liver fat content,34 and subcutaneous 
abdominal and intra-abdominal fat.35 All analyses of the imaging results were performed by one 
person (AH). Subjects were advised to fast for 4 hours before imaging.  
Biochemical Analyses―Lipoprotein fractions [chylomicrons (Sf >400), large VLDL1 particles (Sf 
60–400) and smaller VLDL2 particles (Sf 20–60)] from blood samples drawn before and during the 
fat-rich mixed meal test were separated by density gradient ultracentrifugation.36 Triglyceride and 
cholesterol concentrations in total plasma and lipoprotein fractions were analyzed using the Konelab 
60i analyser (Thermo Fisher Scientific, Finland) TRL cholesterol and remnant-lipoprotein cholesterol 
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were analyzed using automated direct assays (Denka Seiken Co., LTD, Tokyo, Japan). ApoB48 levels 
in total plasma were measured by ELISA (Shibayagi, Shibukawa, Japan). Concentrations of plasma 
glucose were measured using the hexokinase method and insulin with sandwich immunoassays 
(Roche Diagnostic, Germany). Plasma levels of apoC-III were measured immunoturbidometrically 
(Kamiya Biomedical Company, Seattle, WA, USA) and β-hydroxybutyrate concentrations were 
measured by an enzymatic method with β-hydroxybutyrate FS kit (DiaSys Diagnostic Systems, 
Holzheim, Germany) on a Konelab 60i analyzer (Thermo Fisher Scientific, Finland). Plasma non-
esterified fatty acids (NEFA) were analyzed with an automated enzymatic colorimetric method 
(Wako Chemicals, Neuss, Germany). An immunochemical method was used for the selective 
measurement of lipoprotein lipase (LPL) and hepatic lipase (HL) activities in postheparin plasma.37  
Analyses of postprandial synthesis and intestinal absorption of cholesterol and of bile acid 
synthesis―Lipids from plasma samples were extracted by a slightly modified BuMe method,38 
evaporated to dryness under a stream of nitrogen, dissolved in a small volume of methanol and 1 µl 
was injected on the mass spectrometer system. Analysis was performed by supercritical 
chromatography tandem mass spectrometry with atmospheric pressure photoionisation (SFC-APPI-
MS/MS) on a Waters UPC2 chromatograph (Waters Inc, USA) connected to a Xevo TQ-S mass 
spectrometer (Waters, Manchester, UK). Column was a Waters BEH Si 2.1 x 100 mm with 1.7 µm 
particles. The column was held at Flow was 1.7 ml/min and gradient was from 0% MeOH in CO2 to 
6% MeOH in CO2 at 5 min then back to 0% in 0.1 min and equilibrate for 0.5 min. The make-up 
flow was MeOH 0.3 ml/min. The analytes and their respective internal standards were ionized by 
APPI and detected by the following mass spectrometric transitions (M-OH)+: C4, 401.4 => 177.1 CE 
= 20, d7-7-ketocholesterol (I S), 407.2 => 175.1, lanosterol, 409.2 => 191.1 CE = 12, d3-Lanosterol 
412.3 => 191.1 CE = 12, sitosterol, 397.2 => 161 CE=22, d7-Sitosterol, 404.2 => 161 CE = 22. 
Calibration was performed by standards in 6 concentrations ranging from C4, 3.5 to 706 nM, 
Lanosterol, 11.7 to 2340 nM and Sitosterol, 109 to 22000 nM. 
The lanosterol segment of the cholesterol pathway comprises the rate-limiting and committed steps 
of cholesterol biosynthesis, and lanosterol/cholesterol is an established surrogate marker of total body 
cholesterol synthesis.39 Sitosterol is an abundant plant sterols not synthesized in the human body and 
sitosterol/cholesterol is an established surrogate marker of cholesterol absorption.40 The plasma 
oxysterol 7α-hydroxy-4-cholesten-3-one (C4)/cholesterol is used as an index of hepatic bile acid 
synthesis.41 Kinetics of postprandial increase in cholesterol synthesis was calculated by generating 
for each patient a quadratic function. The function variables were the ratios lanosterol/cholesterol and 
time (0, 4 and 8 hours), respectively. The index of the rate of increase in cholesterol synthesis was 
calculated using the first derivative of quadratic function at the given time point (4 and 8 hours).  
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Statistical Analyses―Statistical analyses were performed using the GraphPad Prism, version 7.  
 A repeated measures ANOVA test was used to examine the differences in postprandial 
concentrations of analytes (Figures 1 and 2) before and at the end of the evolocumab intervention. 
T-tests were performed to investigate differences (before vs after intervention) in individual time-
points after the fat-rich mixed meal. To control for multiple testing, false discovery rate was analysed 
using the two-stage step-up method of Benjamini, Krieger and Yekutieli. The significance of 
treatment associated changes in Table 1 were assessed using paired difference t-test; the results did 
not differ whether the test was performed on untransformed data or following transformation to 
logarithmic values. Correlation coefficients and associated p-values were calculated using the non-
parametric Spearman test. P-values in Table 2 were calculated using paired t-test. Differences in 
postprandial kinetics of synthesis and intestinal absorption of cholesterol and of bile acid synthesis 
were calculated using the Wilcoxon signed-rank test. 
RESULTS 
Demographics, body fat depots and glycaemia 
Table 1 presents the characteristics and cardiometabolic biomarker profiles of the 14 type 2 diabetic 
subjects who completed the protocol. We observed no change in body weight, visceral or 
subcutaneous fat depots, or liver fat content following 12 weeks of evolocumab therapy. There were 
no significant changes in fasting glucose, insulin concentration, indexes of insulin sensitivity/insulin 
resistance or HbA1c. Likewise, we did not observe any effect of evolocumab on hepatic de novo 
lipogenesis, fasting β-hydroxybutyrate, or NEFA concentrations. 
Fasting and postprandial lipids  
As expected, evolocumab add-on therapy resulted in marked reductions in fasting total cholesterol 
(-42%), LDL cholesterol (-78%) and apoB (-53%) (Table 1). We did not find any significant changes 
in fasting plasma triglycerides, apoB48 or apoC-III levels. Interestingly, evolocumab therapy 
resulted in a significant 47% reduction of fasting triglyceride-rich-lipoprotein (TRL)-cholesterol 
(measured as the d<1.006 g/ml fraction) but no significant reduction was seen in fasting remnant-
like particle (RLP)-cholesterol (this assay measures the concentration of particles that do not bind to 
anti-apoA-I [HDL] or anti-apoB100 [LDL, IDL and apoB100-containing VLDL]). Fasting apoC-III 
levels were associated with both RLP-cholesterol and TRL-cholesterol values before and during 
evolocumab therapy (r=0.75, p=0.0044 and r=0.79, p=0.0021 respectively). HDL cholesterol and 
apoA1 were increased modestly by the addition of evolocumab (Table 1). No significant changes of 
postheparin plasma activities of LPL or HL were induced by evolocumab (Table 1). 
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Despite no change in fasting plasma triglycerides or apoC-III on evolocumab therapy, we observed 
significantly reduced postprandial responses (analysed as area under the curve [AUC]) in plasma 
total triglycerides, VLDL1-triglycerides, apoC-III and apoB48 (Figure 1). There was a trend to 
reduced AUC for chylomicron triglyceride on evolocumab but this failed to reach significance 
(P=0.053, Figure 1). It was notable that the reductions in postprandial response, where they 
occurred, were in the main seen 4-6 hours after ingestion of the fat-rich mixed meal. Evolocumab 
therapy also reduced the steady state levels of VLDL2-triglycerides (29% decrease, P=0.006) 
throughout the postprandial period (Figure 1). Evolocumab therapy significantly reduced by 44% 
the levels of TRL-cholesterol (P<0.0001), VLDL2 cholesterol level by 50% (P<0.0001), and LDL 
cholesterol by 78% (P<0.0001) both in the fasting state and during the postprandial period (Figure 
2). Despite the lack of impact on mean fasting levels, PCSK9 inhibition significantly reduced the 
postprandial responses of RLP cholesterol (29% reduction in AUC, P<0.0001), and VLDL1 
cholesterol (23% reduction in AUC, P=0.0002). Change in plasma apoC-III on evolocumab showed 
a strong correlation with change in plasma TG values (r= 0.82, P= 0.0008) as well as with change in 
fasting RLP-C and TRL-C (r= 0.81, P=0.0014; and r=0.61, P= 0.030, respectively) (Figure 3 and 
Supplementary Figure S1). 
Effect of evolocumab on total body cholesterol biosynthesis, intestinal cholesterol absorption, 
and bile acid synthesis. 
To investigate whether evolocumab treatment was associated with postprandial changes in 
cholesterol and bile acid metabolism, biomarkers of cholesterol synthesis (lanosterol), intestinal 
cholesterol absorption (sitosterol) and bile acid synthesis (7α-hydroxy-4-cholesten-3-one; C4) were 
measured and normalized to plasma cholesterol concentration (Table 2). PCSK9 inhibition 
increased the lanosterol/cholesterol ratio in the fasting and postprandial states indicating that the 
evolocumab treatment led to an increase in total body cholesterol synthesis (Table 2). Interestingly, 
analysis of dynamics of the postprandial increase of cholesterol synthesis showed higher rates at 4 
and 8 hours after evolucumab treatment (P<0.01 and P<0.05, respectively) (Figure 4). No changes 
were observed in either fasting or postprandial biomarkers for intestinal cholesterol absorption 
(sitosterol/cholesterol ratio; Table 2), or bile acid synthesis (C4/cholesterol ratio; Table 2) either at 




In this study of the effects of PCSK9 inhibition on lipid and lipoprotein responses to a mixed, fat-
rich meal in type 2 diabetic patients, we showed that 12 weeks’ treatment with evolocumab in this 
dyslipidemic condition perturbed postprandial lipid metabolism in a way that was distinct from the 
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action of statins,20-22 and from what has been observed when PCSK9 inhibitors are given to normal 
subjects.22, 29 Evolocumab treatment reduced significantly the postprandial rise in plasma total 
triglyceride, VLDL1-triglyceride, TRL cholesterol, RLP cholesterol, apoC-III and apoB48, while the 
increment in chylomicron triglyceride exhibited a trend that did not achieve significance. It was 
notable that the greatest impact of the drug appeared to occur 4 to 6 hours after meal ingestion; the 
initial postprandial rise (i.e. in the first 4 hours) was virtually identical before and on evolocumab 
therapy. Fasting levels of plasma triglyceride, RLP-C, apoC-III and apoB48 were not influenced by 
treatment. There were, however, substantial significant decreases in the ‘steady state’ – fasting and 
postprandial levels - of VLDL2 triglyceride and cholesterol, LDL cholesterol and apoB.  
In interpreting these findings, it is important to note that the impact of evolocumab was studied on a 
background of moderate dose statin therapy. Statins themselves have effects on post-prandial lipid 
metabolism - reducing the degree of alimentary lipemia, as well as on fasting VLDL levels 15-17.   We 
propose that the addition of evolocumab had two principal actions in these diabetic subjects as shown 
in Figure 5, first an effect on small VLDL (VLDL2) and LDL particles that leads to a marked 
reduction in the circulating concentrations of these lipoprotein classes throughout the day. Second, 
an impact on the removal of postprandial TRL particles and their remnants including apoB48-
containing particles, and VLDL1 remnants which may contain apoB100 or apoB48.
42 Evolocumab 
therapy appeared not to influence the production and release of chylomicrons from the intestine, as 
evidenced by the lack of effect on the total chylomicron response, and especially the initial rise. The 
changes in TRL metabolism were associated with levels of plasma apoC-III, an apoprotein cofactor 
that is known to influence the lipolysis and clearance of TRL particles.14, 43-46 It is clear from these 
findings that a full appreciation of the actions of PCSK9 inhibitors needs to take into account the 
impact of these drugs on triglyceride-rich lipoprotein particles as well as cholesterol transporting 
LDL.  
The effects of PCSK9 inhibition on postprandial lipoprotein metabolism has been reported for 
individuals with normal plasma lipid levels (plasma triglyceride <1.0 mmol/l) 17,22, and in part in 
type 2 diabetics with raised fasting plasma triglyceride 23 (mean of 2.0 mmol/l) where a 2- to 3-hour 
post-meal window was examined. Reyes-Soffer et al 22 examined the impact of alirocumab on the 
apoB-containing lipoprotein spectrum and while the action of the drug on VLDL and LDL kinetics 
was clearly in line with its known mechanism of action, there was no impact on the response in 
plasma triglyceride and apoB48 to a fat test meal. The study of Chan et al,17 again in healthy 
volunteers, compared directly statin therapy which induced a substantial reduction in postprandial 
plasma triglyceride, VLDL cholesterol and apoB48 to evolocumab treatment which had no 
discernible impact on these parameters. They reported further on the kinetics of apoB48, 
documenting an increased clearance rate on statin therapy but again no change on evolocumab. The 
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BANTING study28 in type 2 diabetic subjects found no significant effect of evolocumab on fasting 
plasma triglyceride but a 13.4% to 17.0% decrease respectively in the 2-hour and 3-hour AUC in 
this lipid after a fat meal. Likewise, there was a decrease in chylomicron triglyceride AUC of 7.4-
12.8% and of 8.5 to 14.5% in apoB48 AUC; these modest changes on PCSK9 inhibition were 
recorded as being of variable statistical significance. Overall, the results of the BANTING trial28 are 
in accord with the findings of the present study; the detection of early changes may be attributable 
to the greater subject numbers in the former. However, the short time window employed may have 
limited the ability to detect the more notable effects of the drug which occurred, as mentioned above, 
later after meal ingestion. 
Evolocumab treatment in our type 2 diabetic group was associated with increased levels of 
biomarkers of cholesterol synthesis both in fasting and postprandial state. These findings suggest 
that PCSK9 inhibition decreases the intracellular cholesterol pool (secondary to prolonged exposure 
to very low levels of cholesterol in plasma), and as a consequence, tissues, primarily intestine and 
liver (which account for the majority of whole-body cholesterol synthesis) upregulate cholesterol de 
novo production in order to sustain cellular cholesterol homeostasis. The increase in postprandial 
cholesterol biosynthesis might be necessary to support lipoprotein assembly and secretion of both 
chylomicrons (during absorption of the fat-rich meal) and VLDL (as lipolysed fatty acid are taken 
up by the liver). In contrast, no changes were observed in markers of intestinal cholesterol absorption 
or bile acid synthesis. This observation is in line with the concept that bile acid synthesis is privileged 
and maintained also in condition of low levels of intracellular cholesterol as previously described in 
gallstone patients treated with high doses of statins in the presence or absence of ezetimibe.47, 48 
Advanced bioinformatics investigating liver-specific genes that are co-expressed with fatty acid 
synthase revealed that PCSK9 is linked to NAFLD pathogenesis;49 hepatic PCSK9 expression has 
been shown to be associated with steatosis severity and activation of genes regulating hepatic 
lipogenesis in patients at risk of NASH.50 Data also indicate that circulating PCSK9 levels associate 
with hepatic lipogenesis and liver fat accumulation in humans50, 51 and mice.52 However, it is still 
unclear whether circulating PCSK9 is causatively linked to increased hepatic fat content, or if the 
association merely reflect coordinated expression. Here we found no changes in hepatic fat 
accumulation after evolocumab therapy.  
The limitations of the present metabolic study are the size of the cohort, its design as an open label 
trial, and the fact that for ethical and practical reasons all subjects were placed on a standard 
background regimen of 20 mg/d atorvastatin. In this context it is encouraging to see that our findings 
were in accord with those of the larger BANTING trial.28 Comparing the two studies of type 2 
diabetic subjects given evolocumab in addition to statin therapy, it can be seen that the effects of the 
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PCSK9 inhibitor were similar for plasma triglyceride, a 12.6% reduction in BANTING28 versus 14% 
in Table 1, and for LDL a 65% decrease28 versus 78% in Table 1. 
In summary, 12 weeks’ treatment with evolocumab in type 2 diabetics improved specific aspects of 
the postprandial response of triglyceride-rich lipoprotein to a mixed, fat-rich meal. As depicted in 
Figure 5, the data are consistent with a decrease in the circulating levels of remnant lipoproteins as 
well as small VLDL and LDL. This combined action could lead to enhanced reduction in risk of an 
ASCVD event since remnants are considered in an emerging consensus have an atherogenic 
potential equal to that of LDL. The findings of this study emphasize the importance of taking into 
account not only alterations in fasting values but also postprandial responses when evaluating the 
clinical benefits of novel drug therapies for hyperlipidaemia. It appears also that the action of PCSK9 
inhibitors on postprandial lipoprotein metabolism relates primarily to the level of remnants generated 
during dietary fat absorption which is in turn determined by the prevailing plasma triglyceride 
concentration and efficiency of lipolysis. 
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Table 1. Characteristics of the subjects before and after evolocumab treatment. Data are indicated 
as mean ± SD. Mean absolute changes from baseline to week 12 are shown with ± SD and mean 
percentage changes are indicated in parenthesis. P-values were calculated using a paired difference 








Before After Change P-value 
Weight (kg) 82.7 ± 16 82.8 ± 15 0.1 ± 1.3 (0.15%) 0.74 
BMI (kg/m2) 29.4 ± 4 29.4 ± 3.7 0.1 ± 0.4 (0.18%) 0.68 
Waist (cm) 104 ± 9.9 104 ± 9.6 -0.04 ± 2.6 (-0.037%) 0.96 
Systolic BP (mmHg) 138 ± 16 135 ± 16 -3.7 ± 13 (-2.7%) 0.31 
Diastolic BP (mmHg) 83.8 ± 6.8 79.7 ± 6.6 -4.2 ± 7.4 (-5%) 0.064 
Heart rate (bpm) 66.5 ± 10 69.4 ± 10 2.8 ± 8.3 (4.3%) 0.24 
VAT (cm3) 2420 ± 960 2450 ± 1100 -13.3 ± 230 (-0.55%) 0.84 
SAT (cm3) 3900 ± 1700 4110 ± 1600 8.5 ± 120 (0.22%) 0.81 
Glucose homeostasis     
P-Glucose (mmol/l) 6.3 ± 0.4 6.4 ± 0.8 0.1 ± 0.5 (1.8%) 0.39 
HbA1c (%) 5.9 ± 0.4 6.1 ± 0.5 0.2 ± 0.3 (3.3%) 0.061 
Insulin (µU/ml) 8.9 ± 3.6 10.3 ± 7 1.4 ± 4.9 (16%) 0.31 
HOMA2-%B 66.9 ± 18 65.4 ± 17 -1.5 ± 17 (-2.2%) 0.75 
HOMA2-%S 98.8 ± 56 99.6 ± 53 0.8 ± 41 (0.83%) 0.94 
HOMA2-IR 1.4 ± 0.98 1.2 ± 0.5 -0.2 ± 0.7 (-14%) 0.30 
Lipids and lipoproteins     
Cholesterol (mmol/l) 3.9 ± 0.5 2.2 ± 0.6 -1.7 ± 0.4 (-42%) <0.001 
HDL-C (mmol/l) 1.4 ± 0.4 1.6 ± 0.4 0.2 ± 0.2 (16%) <0.001 
Triglycerides (mmol/l) 1.6 ± 0.5 1.3 ± 0.5 -0.2 ± 0.6 (-14%) 0.18 
LDL-C (mmol/l) 1.7 ± 0.4 0.4 ± 0.2 -1.4 ± 0.4 (-78%) <0.001 
ApoC-III (mg/dl) 12.2 ± 4.3 10.4 ± 5.2 -1.9 ± 3.7 (-15%) 0.093 
ApoB (mg/dl) 75.9 ± 15 35.3 ± 11 -40.5 ± 8.8 (-53%) <0.001 
ApoB48 (mg/l) 6.1 ± 3.8 5.3 ± 3.3 -0.8 ± 2.5 (-13%) 0.27 
ApoA-I (mg/dl) 142 ± 25 151 ± 26 9.5 ± 11 (6.7%) 0.011 
TRL-C (mg/dl) 33.4 ± 11 17.8 ± 6.5 -15.6 ± 7.8 (-47%) <0.001 
RLP-C (mg/dl) 8.5 ± 4.3 7.0 ± 4.7 -1.4 ± 4.4 (-17%) 0.27 
Hepatic lipid metabolism     
DNL (µmol/l) 17.6 ± 13 17.1 ± 12 -0.48 ± 13 (-2.7%) 0.90 
NEFA (µmol/l) 615 ± 210 608 ± 180 -7.2 ± 190 (-1.2%) 0.89 
β-OHB (mg/dl) 0.67 ± 0.24 0.73 ± 0.32 0.05 ± 0.34 (7.9%) 0.59 
Liver fat (%) 6.6 ± 6.6 6.3 ± 7.2 -0.2 ± 1 (-2.5%) 0.59 
LPL activity (mU/ml) 134 ± 52 122 ± 44 -12 ± 53 (-1.9%) 0.44 
HL activity (mU/ml) 227 ± 110 220 ± 89 -9 ± 65 (4.5%) 0.64 
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Table 2. Lanosterol, sitosterol, C4 and their relations to total plasma cholesterol before and 4h and 
8h after fat-rich mixed meal (FRMM). The analyses were performed before and after the 12 weeks 
evolocumab intervention. Lanosterol, sitosterol and C4 were quantified in nmol/L concentrations, 
and total cholesterol in mmol/L concentration. Thus, data are reported as mmol/mol. P-value is 








(mean ± SD) 
After 
intervention 





0h 43.3 ± 15 75.2 ± 27 <0.0001 
4h 73.2 ± 23 134 ± 66 <0.001 
8h 65.5 ± 23 118 ± 38 <0.0001 
 
C4/Tot chol 
0h 15.7 ± 12 18.2 ± 10 0.15 
4h 16.8 ± 11 17.1 ± 11 0.94 
8h 9.94 ± 5.7 9.89 ± 4.2 0.94 
 
Sitosterol/Tot chol 
0h 819 ± 220 871 ± 270 0.18 
4h 898 ± 230 931 ± 390 0.69 






Figure 1. Postprandial responses of triglycerides, apoB48 and apoC-III before (⚫) and after 
evolocumab treatment (). Area under the curve (AUC) was normalized so that 100 % corresponds to the 
AUC before treatment; subsequently the percentage after treatment is in reference to this value. AUC-values 
were calculated using the trapezoidal rule. P-values refer to a repeated measures ANOVA analysis with time 
point (before or after evolocumab) as factor. Stars indicate significant difference (FDR-adjusted t-test) before 
vs after treatment at a particular time point after the meal.  
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Figure 2. Postprandial responses of cholesterol in different fractions and total apoB before (⚫) and 
after evolocumab treatment (). P-values refer to a repeated measures ANOVA analysis with time point 
(before or after evolocumab) as factor. Area under the curve (AUC) was normalized so that 100 % corresponds 
to the AUC before treatment; the percentage after treatment is in reference to this value. 
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Figure 3. Correlation of change in apoC-III after evolocumab intervention with changes in (A) 
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Figure 4. Postprandial rates of increase in cholesterol synthesis. The kinetics were calculated 
by generating for each patient a quadratic function. The rate of cholesterol synthesis was calculated 
using the first derivative of quadratic function at the given time point (4 and 8 hours). Differences in 











































Figure 5. Potential mechanism of action of evolocumab on postprandial lipoprotein 
metabolism. In this scheme which is based on a previous report on the integrated metabolism of 
chylomicrons and VLDL during dietary lipid absorption,42 it is envisaged that the intestine secretes 
apoB48-containing particles into the chylomicron and VLDL density ranges while the liver releases 
apoB100-containing VLDL1 and VLDL2. Remnant particles, the product of partial lipolysis, can 
form in each density interval. Evolocumab treatment (Evo) does not appear to affect chylomicron 
release from the intestine (Evo=). It is known that PCSK9 inhibition substantially increases the 
expression of lipoprotein receptors (especially in the liver) and this leads to accelerated clearance of 
LDL and VLDL particles). Here it is proposed that on evolocumab an abundance of hepatocyte LDL 
receptors (Evo++) increases clearance of remnant particles from the VLDL1 and VLDL2 density 
ranges leading to the decreases seen in the later phase of the postprandial period. Further, there is the 
possibility that small VLDL2 secreted from the liver are immediately taken up again (maybe in the 
Space of Disse), and this leads to the drop in steady state VLDL2 levels. ApoC-III present on TRL 
particles will be reduced as particle clearance is accelerated by the superabundance of receptors. 
  
 



















Supplementary Figure S1. A correlation matrix between changes in metabolic variables after 
PCSK9 inhibition with evolocumab. Number indicates value of spearman correlation coefficient. 
Correlation coefficients with p-value of correlation < 0.05 are shown. 
